Cited by 153Schizophrenia research and treatmentPituitary Gland Disorders and TreatmentsGrowth Hormone and Insulin-like Growth Factors

The DOI matches its Crossref record; 183 of the 184 references it cites were found in a registry or an index.

Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders: Recent Developments and Current Perspectives

Byerly, Matthew, Suppes, Trisha, Tran, Quynh-Van, Baker, Ross A.·2007·Journal of Clinical Psychopharmacology

DOI 10.1097/jcp.0b013e31815ac4e5

Open this paper in CoChat — free account

Abstract

Hyperprolactinemia is increasingly studied as a frequent and potentially important consequence of antipsychotic medication treatment. Some individuals presenting with hyperprolactinemia remain asymptomatic, but others may exhibit a wide range of clinical symptoms resulting from either the direct effects of prolactin on body tissues (galactorrhea, gynecomastia) or endocrine-related secondary effects (sexual and reproductive dysfunction in the short term, and possibly the risk of tumorigenesis and osteoporosis in the longer term). Short-term side effects may negatively impact medication compliance, and long-term effects have the potential for serious health consequences. Antipsychotic medications have differing propensities to cause prolactin elevation. The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. A comprehensive overview of antipsychotics and hyperprolactinemia is presented together with a review of emerging evidence about the short- and long-term health risks of hyperprolactinemia.

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e31815ac4e5

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.
Bôle-Feysot, C., Goffin, V., Edery, M., Binart, N., & Kelly, P. (1998) · Endocrine reviews · doi:10.1210/edrv.19.3.0334 · Cited by 1,973
Does Fast Dissociation From the Dopamine D 2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Relationship Between Dopamine D 2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
Tollefson, G. D., Beasley, C. M., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R., Graffeo, K. A., & Thieme, M. E. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients
Chouinard, G., Jones, B., Remington, G. J., BLOOM, D., Addington, D. E., MacEwan, G. W., Labelle, A., Beauclair, L., & Arnott, W. S. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
Arvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 801

Show all 184 references

Research works printed but not linked: 3

Cook, 1992, Pediatric reference ranges for prolactin., Clin Chem, 38, 959
Kaneda, 2000, Neither gynaecomastia nor galactorrhea is a common side effect of neuroleptics in male patients., Neuroendocrinol Lett, 21, 447
Ansbacher, 1990, Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting., Obstet Gynecol, 76, 895

Sorted by citations

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 369
The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Sex differences in the psychopharmacological treatment of depression
Sramek, J. J., Murphy, M. F., & Cutler, N. R. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.4/ncutler · Cited by 341
Antipsychotic‐Induced Hyperprolactinemia
Bostwick, J. R., Guthrie, S. K., & Ellingrod, V. L. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.1.64 · Cited by 237
Oral paliperidone for schizophrenia
Nussbaum, A. M., & Stroup, T. S. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006369.pub2 · Cited by 195
The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments
Ng, F., Mammen, O. K., Wilting, I., Sachs, G. S., Ferrier, I. N., Cassidy, F., Beaulieu, S., Yatham, L. N., & Berk, M. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00737.x · Cited by 196
Secondary Effects of Antipsychotics: Women at Greater Risk Than Men
Seeman, M. V. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn023 · Cited by 184
High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury
Wilkinson, C. W., Pagulayan, K. F., Petrie, E. C., Mayer, C. L., Colasurdo, E. A., Shofer, J. B., Hart, K. L., Hoff, D., Tarabochia, M. A., & Peskind, E. R. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00011 · Cited by 162
Osteoporosis and fracture risk in people with schizophrenia
Kishimoto, T., Binder, M. D., Carlson, H. E., Manu, P., & Correll, C. U. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328355e1ac · Cited by 121
Asenapine versus olanzapine in acute mania: a double‐blind extension study
McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L. D., Macek, T. A., & Panagides, J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00749.x · Cited by 113
Antipsychotic Medication in Children and Adolescents: A Descriptive Review of the Effects on Prolactin Level and Associated Side Effects
Roke, Y., van Harten, P. N., Boot, A. M., & Buitelaar, J. K. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0120 · Cited by 108
Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis
Cookson, J., Hodgson, R. E., & Wildgust, H. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112442016 · Cited by 97
Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile?
Trifirò, G., Spina, E., & Gambassi, G. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.017 · Cited by 95
Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: A meta-analysis
González-Blanco, L., Greenhalgh, A. M. D., García‐Rizo, C., Fernández-Egea, E., Miller, B. J., & Kirkpatrick, B. W. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.03.018 · Cited by 88
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study
Byerly, M., Marcus, R. N., Tran, Q.-V., Eudicone, J. M., Whitehead, R. E., & Baker, R. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.019 · Cited by 86
Self-citation
A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications
Beary, M., Hodgson, R., & Wildgust, H. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112440512 · Cited by 79
Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review
Binder, M. D., Detraux, J., & Stubbs, B. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1167873 · Cited by 82
Adjunctive Aripiprazole Versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials
Li, X., Tang, Y., & Wang, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070179 · Cited by 77
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics
Montejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., Del Pino-Montes, J., García-Escudero, M. A., García-Rizo, C., González-Pinto, A., et al. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.02.003 · Cited by 75
Dose-Dependent Effects of Adjunctive Treatment With Aripiprazole on Hyperprolactinemia Induced by Risperidone in Female Patients With Schizophrenia
Yasui‐Furukori, N., Furukori, H., Sugawara, N., Fujii, A., & Kaneko, S. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181ee832d · Cited by 74
Drug-induced gynecomastia
Eckman, A., & Dobs, A. S. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802442382 · Cited by 64
Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis
Labad, J., Montalvo, I., González-Rodríguez, A., García‐Rizo, C., Crespo‐Facorro, B., Monreal, J. A., & Palao, D. J. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.04.031 · Cited by 61
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole
Lu, M., Shen, W. W., & Chen, C.-H. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.09.016 · Cited by 58
Consenso español sobre los riesgos y detección de la hiperprolactinemia iatrogénica por antipsicóticos
Montejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., del Pino, J., García Escudero, M. A., García Rizo, C., González-Pinto, A., et al. (2016) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2015.11.003 · Cited by 55
Antipsychotic-Induced Hyperprolactinemia
Johnsen, E., Kroken, R. A., Abaza, M., Olberg, H. K., & Jørgensen, H. A. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818ba5d8 · Cited by 53
Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review
Bo, Q., Wang, Z., Li, X., Ma, X., Wang, C., & de León, J. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.01.031 · Cited by 52
A review of the safety and tolerability of aripiprazole
Pae, C. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902835493 · Cited by 50
Evidence for the Partial Dopamine-Receptor Agonist Aripiprazole as a First-Line Treatment of Psychosis in Patients With Iatrogenic or Tumorogenic Hyperprolactinemia
Hoffer, Z. S., Roth, R. L., & Mathews, M. (2009) · Psychosomatics · doi:10.1176/appi.psy.50.4.317 · Cited by 49
Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
Berman, R., Berman, R., Thase, M., Trivedi, M. H., Hazel, Marler, McQuade, Carson, Baker, R. A., & Marcus, R. N. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s18333 · Cited by 50
Self-citation
Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies
Stojkovic, М., Radmanović, B., Jovanović, M., Janjic, V. S., Muric, N. N., & Ristić, D. I. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.874705 · Cited by 48
The Diagnosis and Treatment of Bipolar Disorder
Culpepper, L. (2014) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13r01609 · Cited by 49
Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review
Binder, M. D., Detraux, J., & Peuskens, J. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.906579 · Cited by 51
Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia
Thomas, P., Alptekın, K., Gheorghe, M., Mauri, M., Olivares, J. M., & Riedel, M. J. (2009) · CNS Drugs · doi:10.2165/00023210-200923030-00002 · Cited by 45
Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia
Ivkovic, J., Lindsten, A., George, V., Eriksson, H., & Hobart, M. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000979 · Cited by 41
Hyperprolactinemia and medications for bipolar disorder: Systematic review of a neglected issue in clinical practice
Pacchiarotti, I., Murru, A., Kotzalidis, G. D., Bonnín, C. D. M., Mazzarini, L., Colom, F., & Vieta, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.007 · Cited by 40
Management of Psychosis Associated With a Prolactinoma: Case Report and Review of the Literature
Ali, S. N., Miller, K. K., & Freudenreich, O. (2010) · Psychosomatics · doi:10.1016/s0033-3182(10)70718-0 · Cited by 40
Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia
Montejo, A. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo‐Facorro, B., Cruz, J. J., del Pino, J., Escudero, M. A. G., García‐Rizo, C., González-Pinto, A. M., et al. (2016) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2016.06.001 · Cited by 40
Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials.
Meng, M., Li, W., Zhang, S., Wang, H., Sheng, J., Wang, J., & Li, C. (2015) · Europe PMC (PubMed Central) · doi:10.11919/j.issn.1002-0829.215014 · Cited by 38
Schizophrenia: Women Bear a Disproportionate Toll of Antipsychotic Side Effects
Seeman, M. V. (2010) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390309350918 · Cited by 37
Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials
Zheng, W., Yang, X.-H., Cai, D.-B., Ungvari, G. S., Ng, C. H., Wang, N., Ning, Y.-P., & Xiang, Y. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699630 · Cited by 38
A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents
Krøigaard, S. M., Clemmensen, L., Tarp, S., & Pagsberg, A. K. (2022) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0140 · Cited by 39
Prolactinomas
Wildemberg, L. E., Fialho, C., & Gadelha, M. R. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104080 · Cited by 36
Effect of the Addition of Aripiprazole on Hyperprolactinemia Associated With Risperidone Long-Acting Injection
Trives, M. Z., Llácer, J. M. B., Escudero, M. A. G., & Pastor, C. J. M. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182970431 · Cited by 35
The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort
Takahashi, T., Uchida, H., John, M., Hirano, J., Watanabe, K., Mimura, M., Correll, C. U., & Kishimoto, T. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.04.015 · Cited by 34
Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone
Lee, B. J., Lee, S., Kim, M. K., Lee, J. G., Park, S. W., Kim, G. M., & Kim, Y. H. (2013) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2013.11.2.60 · Cited by 34
Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone
Qiao, Y., Yang, F., Li, C., Guo, Q., Wen, H., Zhu, S., Ouyang, Q., Shen, W., & Sheng, J. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.12.033 · Cited by 34
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data
Tsuboi, T., Bies, R. R., Suzuki, T., Mamo, D. C., Pollock, B. G., Graff‐Guerrero, A., Mimura, M., & Uchida, H. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.010 · Cited by 33
The search for new biomarkers for cognition in schizophrenia
Penadés, R., García‐Rizo, C., Bioque, M., González-Rodríguez, A., Cabrera, B., Mezquida, G., & Bernardo, M. (2015) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2015.10.004 · Cited by 34
Recomendaciones para el cambio de antipsicóticos. Posicionamiento de la Sociedad Española de Psiquiatría y Sociedad Española de Psiquiatría Biológica
Bernardo, M., Vieta, E., Ruiz, J. S., Rico‐Villademoros, F., Álamo, C., & Bobes, J. (2011) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2011.07.003 · Cited by 31
Effect of prescription medications on erectile dysfunction
Razdan, S., Greer, A. B., Patel, A. S., Alameddine, M., Jue, J. S., & Ramasamy, R. (2017) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2017-135233 · Cited by 29
Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia
Xiang, Y., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., & Shinfuku, N. (2015) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796015000694 · Cited by 28
Long-Term Effect of Haloperidol, Olanzapine, and Risperidone on Plasma Prolactin Levels in Patients With First-Episode Psychosis
Pérez‐Iglesias, R., Mata, I. F., Martínez‐García, O., García‐Unzueta, M. T., Amado, J., Valdizán, E. M., Vázquez‐Barquero, J. L., & Crespo‐Facorro, B. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318272688b · Cited by 27
How Hyperprolactinemia Affects Sexual Function in Patients Under Antipsychotic Treatment
Rubio‐Abadal, E., Cacho, N. D., Saenz-Navarrete, G., Arranz, B., Cambra, R. M., Cuadras, D., Rodante, D., Fehér, C., Roca, M., Barneda, V., et al. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000539 · Cited by 27
Biochemical diagnosis in prolactinomas: some caveats
Petersenn, S. (2019) · Pituitary · doi:10.1007/s11102-019-01024-z · Cited by 26
Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance
Neumeier, M. S., Homan, S., Vetter, S., Seifritz, E., Kane, J. M., Huhn, M., Leucht, S., & Homan, P. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab078 · Cited by 24
Prolactin serum levels correlate with inflammatory status in drug-naïve first-episode schizophrenia
Song, X., Fan, X., Zhang, J., Zheng, H., Li, X., Pang, L., Chen, X., Zhang, W., Harrington, A., Ziedonis, D. M., et al. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.922699 · Cited by 24
A randomized, 13‐week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first‐episode schizophrenia patients☆
Huang, M.-L., Yu, L., Pan, F., Lu, S.-J., Hu, S.-H., Hu, J.-B., Chen, J., Jin, P., Qi, H.-L., & Xu, Y. (2018) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.021 · Cited by 21
Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents.
Jerrell, J., Bacon, J., Burgis, J., & Menon, S. (2009) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2008.11.010 · Cited by 21
The Discovery and Development of Pharmacotherapy for Psychiatric Disorders: A Critical Survey of Animal and Translational Models and Perspectives for Their Improvement
Millan, M. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00001-1 · Cited by 22
Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001–2009)
Xiang, Y., Li, Y., Correll, C. U., Ungvari, G. S., Chiu, H. F. K., Lai, K. Y. C., Tang, Q., Hao, W., Si, T., Wang, C., et al. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4011 · Cited by 21
Effects of Adjunctive Aripiprazole on Sexual Functioning in Patients With Major Depressive Disorder and an Inadequate Response to Standard Antidepressant Monotherapy
D, M. F. M., Dording, C. M., Baker, R. A., Mankoski, R. E., Tran, Q.-V., Forbes, R. A., Eudicone, J. M., Owen, R., & Berman, R. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.10m00994gre · Cited by 22
Self-citation
Aripiprazole in pediatric psychosis and bipolar disorder: A clinical review
Doey, T. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.02.031 · Cited by 20
Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients
An, F., Yang, R., Wang, Z., Ungvari, G. S., Ng, C. H., Chiu, H. F. K., Wu, P., Jin, X., Li, L., Lok, K.-I., et al. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.08.009 · Cited by 19
Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review
Besag, F., Vasey, M. J., & Salim, I. (2021) · CNS Drugs · doi:10.1007/s40263-021-00812-1 · Cited by 19
Sexual Dysfunction and Hyperprolactinemia in Male Psychotic Inpatients: A Cross-Sectional Study
Johnsen, E., Kroken, R. A., Løberg, E., Kjelby, E., & Jørgensen, H. A. (2011) · Advances in Urology · doi:10.1155/2011/686924 · Cited by 19
Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers
Yasui‐Furukori, N., Ishioka, M., Sugawara, N., Furukori, H., Kudo, S., & Nakamura, K. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75176 · Cited by 18
A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting
Hsieh, M., Lin, W., Chen, S., Chen, K.-C., Chen, K., Chiu, N., Huang, C., Chang, C., Lin, C., & Lai, T. (2010) · Annals of General Psychiatry · doi:10.1186/1744-859x-9-35 · Cited by 18
Women’s Psychiatry
Balta, G., Dalla, C., & Kokras, N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9721-0_11 · Cited by 18
Physical health monitoring for people with schizophrenia
Castle, D. J., & Li, A. (2023) · Australian Prescriber · doi:10.18773/austprescr.2023.024 · Cited by 17
Hyperprolactinemia induced by low‐dosage amisulpride in Korean psychiatric patients
Lee, B., Kang, S., Kim, T., Lee, H., Yoon, H., & Park, Y. (2012) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02296.x · Cited by 17
Hyperprolactinaemia During Treatment With Paliperidone
Skopek, M., & Manoj, P. (2010) · Australasian Psychiatry · doi:10.3109/10398561003686763 · Cited by 17
Effect of Brexpiprazole on Prolactin and Sexual Functioning
Clayton, A. H., Ivkovic, J., Chen, D., George, V., & Hobart, M. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001297 · Cited by 20
Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients
Houston, J., Fijal, B. A., Heinloth, A. N., & Adams, D. H. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2009.06.014 · Cited by 17
Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry
Bernardo, M., Vieta, E., Ruiz, J. S., Rico‐Villademoros, F., Álamo, C., & Bobes, J. (2011) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2011.07.001 · Cited by 15
The Dose-Dependent Effect of Chronic Administration of Haloperidol, Risperidone, and Quetiapine on Sexual Behavior in the Male Rat
Zhang, X. R., Zhang, Z. J., Jenkins, T. A., Cheng, W. R., & Reynolds, G. P. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01740.x · Cited by 15
Frequency of Hyperprolactinemia and Its Associations With Demographic and Clinical Characteristics and Antipsychotic Medications in Psychiatric Inpatients in China
Wang, Z., Xiang, Y., An, F., Correll, C. U., Ungvari, G. S., Wang, C., Lai, K. Y. C., Bo, Q., Li, Y., Zhong, B., et al. (2013) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12050 · Cited by 15
Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance
Bo, Q., Wang, X., Liu, X., Sang, H., Xun, Z., Zhang, R., Yang, X., Deng, H., Li, K., Chen, J., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04598-y · Cited by 14
Effectiveness of long-acting paliperidone palmitate in borderline personality disorder
Palomares, N., Montes, A., Díaz‐Marsá, M., & Carrasco, J. L. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000095 · Cited by 14
Pharmacokinetics and central nervous system effects of the novel dopamine D 2 receptor antagonist JNJ-37822681
Beek, E. T. T., Moerland, M., de Boer, P., Nueten, L. V., de Kam, M. L., Burggraaf, J., Cohen, A. F., & van Gerven, J. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111415733 · Cited by 13
Low-Dose Amisulpride and Elevation in Serum Prolactin
Andrade, C. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13f08510 · Cited by 13
An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate
Einarson, T. R., Hemels, M. E. H., Nuamah, I. F., Gopal, S., Coppola, D., & Hough, D. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r123 · Cited by 13
Guidelines for Antipsychotic-Induced Hyperprolactinemia
Miyamoto, B. E., Galecki, M., & Francois, D. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150501-09 · Cited by 13
Prolactin Level Changes according to Atypical Antipsychotics Use: A Study Based on Clinical Data Warehouse
Kim, S., Jeong, J., Um, Y. H., Kim, T., Seo, H., & Hong, S. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1057 · Cited by 12
Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review
Druyts, E., Zoratti, M. J., Toor, K., Wu, P., Kanji, S., Rabheru, K., Mills, E. J., & Thorlund, K. (2016) · BMC Pediatrics · doi:10.1186/s12887-016-0710-y · Cited by 12
Adjunctive Peony‐Glycyrrhiza decoction for antipsychotic‐induced hyperprolactinaemia: a meta‐analysis of randomised controlled trials
Zheng, W., Cai, D.-B., Li, H., Wu, Y.-J., Ng, C. H., Ungvari, G. S., Xie, S., Shi, Z.-M., Zhu, X.-M., Ning, Y.-P., et al. (2018) · General Psychiatry · doi:10.1136/gpsych-2018-100003 · Cited by 12
Prolactin Level in Patients with First Episode Schizophrenia Treated for One Year with Atypical Antipsychotics
Matei, V. P. (2018) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2018.483 · Cited by 8
Female-specific health problems in mental patients
Akdeniz, F. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833ae437 · Cited by 8
Comparison of treatment patterns in schizophrenia between China and Japan (2001‐2009)
Xiang, Y., Kato, T. A., Kishimoto, T., Ungvari, G. S., Chiu, H. F. K., Si, T., Yang, S., Fujii, S., Ng, C. H., & Shinfuku, N. (2017) · Asia-Pacific Psychiatry · doi:10.1111/appy.12277 · Cited by 7
The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
Yasui‐Furukori, N., Hashimoto, K., Sugawara, N., Ishioka, M., & Nakamura, K. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s68298 · Cited by 7
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients
Yasui‐Furukori, N., Furukori, H., Sugawara, N., Tsuchimine, S., Fujii, A., Inoue, Y., & Kaneko, S. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1110 · Cited by 7
Hyperprolactinaemia: A guide for psychiatrists
Wadoo, O., Shah, A. J., Hall, R., & Mamoojee, Y. H. (2017) · BJPsych Advances · doi:10.1192/apt.bp.115.014977 · Cited by 6
Hyperprolactinemia in Adults with Prader-Willi Syndrome
Sjöström, A., Pellikaan, K., Sjöström, H., Goldstone, A. P., Grugni, G., Crinò, A., de Graaff, L. C. G., & Höybye, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163613 · Cited by 6
Melperone, an aytpical antipsychotic drug with clozapine‐like effect on plasma prolactin: contrast with typical neuroleptics
Bobo, W. V., Jayathilake, K., Lee, M. A., & Meltzer, H. Y. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1036 · Cited by 6
Pharmacological hyperprolactinemia: a retrospective analysis of 501 hyperprolactinemia cases in primary care setting
Cano, A. M. G., Rosillo, M., Lozano, A. G., Mendiguchía, L. J., Pinedo, M. M., Torres, A. R., & Castro, M. A. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02803-z · Cited by 5
Mechanisms of adverse mammary effect induced by olanzapine and therapeutic interventions in rat model.
Dong, Y., Sun, X., Li, H., Han, C., Zhang, Y., Ding, H., Xia, L., Wang, H., Yang, S., Xu, L., et al. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116876 · Cited by 5
Evaluation of prolactin levels in male patients with first-episode schizophrenia and its correlation with psychopathology
Taweel, M. E. S. E., & Abdalla, A. M. (2017) · Middle East Current Psychiatry · doi:10.1097/01.xme.0000513069.03258.07 · Cited by 5
Clinical psychopharmacology
Owens, D. G. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-3137-3.00011-5 · Cited by 5
Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report
Yang, H.-J., Kim, S.-G., Seo, E. H., & Yoon, H. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03721-9 · Cited by 4

Authors: Byerly, M., Suppes, T., Tran, Q.-V., & Baker, R. A.
Affiliations: The University of Texas Southwestern Medical Center (US)
Otsuka (United States) (US)
Bristol-Myers Squibb (United States) (US)
Corresponding author: Byerly, Matthew
Suppes, Trisha
ORCID: Byerly, Matthew
Suppes, Trisha
Baker, Ross A.
Venue: Journal of Clinical Psychopharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2007-12
Volume: 27
Issue: 6
Pages: 639-661
ISSN: 0271-0749 (ISSN-L)
DOI: 10.1097/jcp.0b013e31815ac4e5
OpenAlex: W1965091910
Cited by: 153
References: 184
Citations by year: 2026: 7 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 7 · 2020: 3 · 2019: 3 · 2018: 7 · 2017: 10 · 2016: 10 · 2015: 11 · 2014: 11 · 2013: 10 · 2012: 9
FWCI: 1.56
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords: antipsychotic-induced hyperprolactinemia, schizophrenia spectrum disorders, bipolar spectrum disorders, typical antipsychotics, atypical antipsychotics, risperidone, paliperidone, galactorrhea, gynecomastia, sexual dysfunction, reproductive disorders, carcinogenesis, osteoporosis, medication adherence, long-term health risks
MeSH terms: Bipolar Disorder, Humans, Hyperprolactinemia, Models, Biological, Psychopharmacology, Schizophrenia, Antipsychotic Agents, Meta-Analysis as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders: Recent Developments and Current Perspectives

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks